Skip to main content
Erschienen in: Pathology & Oncology Research 2/2012

01.04.2012 | Research

Periacinar Retraction Clefting in Nonneoplastic and Neoplastic Prostatic Glands: Artifact or Molecular Involvement

verfasst von: Wagner José Fávaro, Amanda Cia Hetzl, Leonardo Oliveira Reis, Ubirajara Ferreira, Athanase Billis, Valéria Helena A. Cagnon

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

A space between neoplastic acini and prostatic stroma is not rare and studies have interpreted this as an artifact, considering the absence of endothelial cells indicating vascular invasion. Thus, the aims of this work were to characterize and correlate the occurrence and extent of retraction clefting with the reactivities of α and β dystroglycan (αDG, βDG), laminin, matrix metalloproteinase 2 (MMP-2), p63, insulin-like growth factor 1(IGF-1), vimentin, and fibroblast growth factor 2 (FGF-2). The study was based on nonneoplastic and neoplastic prostatic tissues obtained from necropsies and retropubic radical prostatectomies. The results showed that periacinar retraction clefting was significantly more frequent in prostatic carcinoma samples than in normal prostatic acini. Most of the neoplastic acini (72.0%) showed retraction clefting of more than 50% of circumference, which were significantly more frequent in Gleason score 7 and 6. Decreased collagen and reticular and elastic fibers were verified in the stroma around neoplastic acini. Weak and discontinuous αDG, βDG, and laminin immunoreactivities and intensified MMP-2, vimentin, IGF-1 and FGF-2 immunoreactivities were verified in the neoplastic acini; p63 immunoreactivity was negative in all carcinomas. Thus, these findings showed that the lack of epithelial basal cells, DGs, and laminin and increased MMP-2, IGF-1, and FGF-7 could be considered important pathways in periacinar retraction occurrence. This study demonstrated the origin of and the biological mechanisms responsible for periacinar retraction clefting in prostatic carcinoma.
Literatur
1.
Zurück zum Zitat Epstein JI (1995) Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 26:223–229PubMedCrossRef Epstein JI (1995) Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 26:223–229PubMedCrossRef
2.
Zurück zum Zitat Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PGO, Amin MB (2002) Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. Arch Pathol Lab Med 126:554–561PubMed Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PGO, Amin MB (2002) Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. Arch Pathol Lab Med 126:554–561PubMed
3.
Zurück zum Zitat Krušlin B, Tomas D, Rogatsch H, Novosel I, Cupić H, Belicza M, Kraus O, Mikuz G (2003) Periacinar retraction clefting in the prostatic needle core biopsies: an important diagnostic criterion or a simple artifact? Virchows Arch 443:524–527PubMedCrossRef Krušlin B, Tomas D, Rogatsch H, Novosel I, Cupić H, Belicza M, Kraus O, Mikuz G (2003) Periacinar retraction clefting in the prostatic needle core biopsies: an important diagnostic criterion or a simple artifact? Virchows Arch 443:524–527PubMedCrossRef
4.
Zurück zum Zitat Baisden BL, Kahane H, Epstein JI (1999) Perineural invasion, mucinous fibroplasia and glomerulations: diagnostic features on prostate needle biopsy. Am J Surg Pathol 23:918–924PubMedCrossRef Baisden BL, Kahane H, Epstein JI (1999) Perineural invasion, mucinous fibroplasia and glomerulations: diagnostic features on prostate needle biopsy. Am J Surg Pathol 23:918–924PubMedCrossRef
5.
Zurück zum Zitat Durham JR, Lee MW, Amin MB, Shulz DS, Stetler-Stevenson WG (1994) Clefting in adenocarcinoma of the prostate gland. Am J Clin Pathol 102:536 Durham JR, Lee MW, Amin MB, Shulz DS, Stetler-Stevenson WG (1994) Clefting in adenocarcinoma of the prostate gland. Am J Clin Pathol 102:536
6.
Zurück zum Zitat Krušlin B, Novosel I, Reljić A, Čupić H, Spajić B, Belicza M (2002) Periacinar cleft-like spaces in prostatic needle core biopsies. Acta Clin Croat 41:175 Krušlin B, Novosel I, Reljić A, Čupić H, Spajić B, Belicza M (2002) Periacinar cleft-like spaces in prostatic needle core biopsies. Acta Clin Croat 41:175
7.
Zurück zum Zitat Krušlin B, Tomas D, Cviko A (2006) Periacinar retraction clefting and p63 immunostaining in prostatic intraepithelial neoplasia and prostatic carcinoma. Pathol Oncol Res 12:205–209PubMedCrossRef Krušlin B, Tomas D, Cviko A (2006) Periacinar retraction clefting and p63 immunostaining in prostatic intraepithelial neoplasia and prostatic carcinoma. Pathol Oncol Res 12:205–209PubMedCrossRef
8.
Zurück zum Zitat Dean JP, Nelson PS (2008) Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 98:245–249PubMedCrossRef Dean JP, Nelson PS (2008) Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 98:245–249PubMedCrossRef
9.
Zurück zum Zitat Cornell RJ, Rowley D, Wheller T (2003) Neuroepithelial interactions in prostate cancer are enhanced in the presence of prostatic stroma. Urology 61:870–875PubMedCrossRef Cornell RJ, Rowley D, Wheller T (2003) Neuroepithelial interactions in prostate cancer are enhanced in the presence of prostatic stroma. Urology 61:870–875PubMedCrossRef
10.
Zurück zum Zitat Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, Cangiano R, Losasso C, Capelli G, Trentini GP, Cittadini A (2003) Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 162:849–860PubMedCrossRef Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, Cangiano R, Losasso C, Capelli G, Trentini GP, Cittadini A (2003) Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 162:849–860PubMedCrossRef
11.
Zurück zum Zitat Brennan PA, Jing J, Ethunandan M, Gorecki D (2004) Dystroglycan complex in cancer. Eur J Surg Oncol 30:589–592PubMedCrossRef Brennan PA, Jing J, Ethunandan M, Gorecki D (2004) Dystroglycan complex in cancer. Eur J Surg Oncol 30:589–592PubMedCrossRef
12.
Zurück zum Zitat Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, Faraglia B, Boninsegna A, Maiorana A, Cittadini A (2007) Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 213:528–539PubMedCrossRef Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, Faraglia B, Boninsegna A, Maiorana A, Cittadini A (2007) Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 213:528–539PubMedCrossRef
13.
Zurück zum Zitat Djavan B, Waldert M, Seitz C, Marberger M (2001) Insulin-like growth factors and prostate cancer. World J Urol 19:225–233PubMedCrossRef Djavan B, Waldert M, Seitz C, Marberger M (2001) Insulin-like growth factors and prostate cancer. World J Urol 19:225–233PubMedCrossRef
14.
Zurück zum Zitat Reynolds AR, Kyprianou N (2006) Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol 2:S144–S152CrossRef Reynolds AR, Kyprianou N (2006) Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol 2:S144–S152CrossRef
15.
Zurück zum Zitat Mostofi FK, Price EBJr (1973) Tumors of the male genital system, atlas of tumor pathology, second series, fascicle 8. Armed Forces Institute of Pathology, Washington, pp 202–217 Mostofi FK, Price EBJr (1973) Tumors of the male genital system, atlas of tumor pathology, second series, fascicle 8. Armed Forces Institute of Pathology, Washington, pp 202–217
16.
Zurück zum Zitat Tomas D, Krušlin B (2004) The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate 61:324–331PubMedCrossRef Tomas D, Krušlin B (2004) The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate 61:324–331PubMedCrossRef
17.
Zurück zum Zitat Halpert B, Sheehan EA, Schmalhorst WR, Scott RJ (1963) Carcinoma of the prostate: a survey of 5000 autopsies. Cancer 16:736–742CrossRef Halpert B, Sheehan EA, Schmalhorst WR, Scott RJ (1963) Carcinoma of the prostate: a survey of 5000 autopsies. Cancer 16:736–742CrossRef
18.
Zurück zum Zitat Krušlin B, Tomas D, Rogatsch H, Reljić A, Vucić M, Balicević D, Belicza M, Mikuz G (2005) Correlation of periacinar retraction clefting in needle core biopsies and corresponding prostatectomy specimens of patients with prostatic adenocarcinoma. Int J Surg Pathol 13:67–72PubMedCrossRef Krušlin B, Tomas D, Rogatsch H, Reljić A, Vucić M, Balicević D, Belicza M, Mikuz G (2005) Correlation of periacinar retraction clefting in needle core biopsies and corresponding prostatectomy specimens of patients with prostatic adenocarcinoma. Int J Surg Pathol 13:67–72PubMedCrossRef
19.
Zurück zum Zitat Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL (1998) Atlas of tumor pathology. AFIP, Washington, pp 124–171 Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL (1998) Atlas of tumor pathology. AFIP, Washington, pp 124–171
20.
Zurück zum Zitat Tomas D, Ulamec M, Hudolin T (2006) Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma. Prostate Cancer Prostatic Dis 9:414–419PubMedCrossRef Tomas D, Ulamec M, Hudolin T (2006) Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma. Prostate Cancer Prostatic Dis 9:414–419PubMedCrossRef
21.
Zurück zum Zitat Tomas D, Spajić B, Milošević M, Demirović A, Marušić Z, Krušlin B (2011) Extensive retraction artefact predicts biochemical recurrence-free survival in prostatic carcinoma. Histopathology 58:447–454PubMedCrossRef Tomas D, Spajić B, Milošević M, Demirović A, Marušić Z, Krušlin B (2011) Extensive retraction artefact predicts biochemical recurrence-free survival in prostatic carcinoma. Histopathology 58:447–454PubMedCrossRef
22.
Zurück zum Zitat Djakiew D (2000) Deregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42:150–160PubMedCrossRef Djakiew D (2000) Deregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42:150–160PubMedCrossRef
23.
Zurück zum Zitat Stangelberger A, Schally AV, Jl V, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M (2005) Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HERfam ily in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 64:303–315PubMedCrossRef Stangelberger A, Schally AV, Jl V, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M (2005) Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HERfam ily in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 64:303–315PubMedCrossRef
24.
Zurück zum Zitat Garrison JB, Kyprianou N (2004) Novel targeting of apoptosis pathways for prostate cancer therapy. Cur Cancer Drug Targets 4:85–95CrossRef Garrison JB, Kyprianou N (2004) Novel targeting of apoptosis pathways for prostate cancer therapy. Cur Cancer Drug Targets 4:85–95CrossRef
25.
Zurück zum Zitat Stattin P, Rinaldi S, Biessy C, Stenman Uh, Hallmans G, Kaaks R (2004) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22:3104–3112PubMedCrossRef Stattin P, Rinaldi S, Biessy C, Stenman Uh, Hallmans G, Kaaks R (2004) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22:3104–3112PubMedCrossRef
26.
Zurück zum Zitat Kwabi-Addo B, Ozen M, Ittmann M (2004) The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11:709–724PubMedCrossRef Kwabi-Addo B, Ozen M, Ittmann M (2004) The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11:709–724PubMedCrossRef
27.
Zurück zum Zitat Aigner A, Butscheid M, Kunkel P, Krause E, Lamszus K, Wellstein A, Czubayko F (2001) An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 92:510–517PubMedCrossRef Aigner A, Butscheid M, Kunkel P, Krause E, Lamszus K, Wellstein A, Czubayko F (2001) An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 92:510–517PubMedCrossRef
28.
Zurück zum Zitat Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063–1071PubMed Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063–1071PubMed
29.
Zurück zum Zitat Lynch C, Matrisian L (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–573PubMedCrossRef Lynch C, Matrisian L (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–573PubMedCrossRef
30.
Zurück zum Zitat Ross J, Kaur P, Sheehan C, Hugh B, Fisher H, Kauffman R, Kallakury B (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198–205PubMedCrossRef Ross J, Kaur P, Sheehan C, Hugh B, Fisher H, Kauffman R, Kallakury B (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198–205PubMedCrossRef
31.
Zurück zum Zitat Martin MD, Matrisian LM (2007) The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26:717–724PubMedCrossRef Martin MD, Matrisian LM (2007) The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26:717–724PubMedCrossRef
32.
Zurück zum Zitat Mack CF, Knox JD, Powell WC, Nagle RB, Bowden GT (1993) Functional-role of the metalloproteinase matrilysin in human prostate-cancer. Int J Radiat Oncol Biol Phys 27:217 Mack CF, Knox JD, Powell WC, Nagle RB, Bowden GT (1993) Functional-role of the metalloproteinase matrilysin in human prostate-cancer. Int J Radiat Oncol Biol Phys 27:217
33.
Zurück zum Zitat Gianelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson W, Quaranta V (1997) Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277:225–228CrossRef Gianelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson W, Quaranta V (1997) Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277:225–228CrossRef
34.
Zurück zum Zitat Yamada H, Saito F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, Okuyama A, Maekawa R, Shimizu T, Matsumura K (2001) Processing of β-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 10:1563–1569PubMedCrossRef Yamada H, Saito F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, Okuyama A, Maekawa R, Shimizu T, Matsumura K (2001) Processing of β-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 10:1563–1569PubMedCrossRef
35.
Zurück zum Zitat Henry MD, Cohen MB, Campbell KP (2001) Reduced expression of dystroglican in breast and prostate cancer. Hum Pathol 32:791–795PubMedCrossRef Henry MD, Cohen MB, Campbell KP (2001) Reduced expression of dystroglican in breast and prostate cancer. Hum Pathol 32:791–795PubMedCrossRef
36.
Zurück zum Zitat Gilles C, Thompson EW (1996) The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J 2:83–96CrossRef Gilles C, Thompson EW (1996) The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J 2:83–96CrossRef
37.
Zurück zum Zitat Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMedCrossRef Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMedCrossRef
38.
Zurück zum Zitat Zhao Y, Yan Q, Long X, Chen X, Wang Y (2008) Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 26:571–577PubMedCrossRef Zhao Y, Yan Q, Long X, Chen X, Wang Y (2008) Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 26:571–577PubMedCrossRef
Metadaten
Titel
Periacinar Retraction Clefting in Nonneoplastic and Neoplastic Prostatic Glands: Artifact or Molecular Involvement
verfasst von
Wagner José Fávaro
Amanda Cia Hetzl
Leonardo Oliveira Reis
Ubirajara Ferreira
Athanase Billis
Valéria Helena A. Cagnon
Publikationsdatum
01.04.2012
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2012
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9440-5

Weitere Artikel der Ausgabe 2/2012

Pathology & Oncology Research 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.